-
News
PMDA received an application for a clinical trial for the IND package of GAIA-102 i.v.
-
News
New Funding by AMED for a Clinical Trial of GAIA-102 to Treat Malignant Ascites
-
News
GAIA BioMedicine Raised a Total of JPY 650 Million in Series A Round.
-
Media
Nikkei Biotech ONLINE – GAIA BioMedicine is now developing allogeneic natural killer (NK)-like cell therapy for solid tumors –
-
Media
An article published in the Nihon Keizai Shimbun. – Allogeneic natural killer (NK)-like cell therapy for solid tumors –
-
News
Our President & CEO Kazu Kuramori was at the Innate Killer Summit 2019 – Title:GAIA-102 as an NK Cell-Based “Upward Compatible” Modality Over CAR-T-Cell Therapy –
-
News
GAIA BioMedicine has released an experimental kit to produce highly activated NK-like cells for research use
-
Media
Nikkei Biotech ONLINE – A venture company aiming at practical application of cell medicine for cancer using NK cells –